OncXerna Therapeutics Announces New Biomarker Data from Retrospective Analysis of Results from Phase 1b Ovarian Cancer Trial of Navicixizumab Plus Paclitaxel at the ESGO 2021 Congress
62% vs. 25% overall response rates with navicixizumab plus paclitaxel in biomarker positive vs. biomarker negative patients using the Xerna™ TME...